Verrica Pharmaceuticals Inc. (NASDAQ: VRCA)

Verrica Pharmaceuticals Inc. (VRCA) is a company that operates in the dermatology therapeutics industry. It specializes in the development and sale of medications for skin diseases that necessitate medical intervention. The company's primary focus is on creating clinician-administered therapies for areas of high unmet need. Verrica's product portfolio includes one approved product, YCANTH (formerly referred to as VP-102), and two additional pipeline products.

YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin, a novel 0.7% w/v topical solution. This product is the first FDA-approved treatment for molluscum contagiosum, a highly contagious skin disease caused by a pox virus. Molluscum contagiosum typically presents with 10 to 30 lesions and can persist for an average of 13 months. The symptoms of this disease can cause significant anxiety, leading parents to frequently seek treatment due to its highly contagious nature and physical appearance. Verrica has commercialized YCANTH (VP-102) in the United States by building a specialized sales organization focused on pediatric dermatologists, dermatologists, and select pediatricians.

In addition to molluscum contagiosum, Verrica is also developing YCANTH (VP-102) for the treatment of common warts, which are warts located on the bottom of the foot. An estimated one-third of the approximately 4.1 million annual patient visits for all types of warts are for the treatment of plantar warts. Verrica is conducting necessary drug development activities for VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts.

Furthermore, Verrica is developing two other product candidates. VP-315 is an oncolytic peptide-based injectable therapy for the potential treatment of dermatological oncologic conditions, including basal cell carcinoma. VP-103 is a second cantharidin-based drug-device combination for the potential treatment of plantar warts.

Verrica's competitive advantages lie in its proprietary drug-device combination and convenient ease of administration. The company's products are designed to address the significant limitations of current therapies, including pain and discomfort, scarring, and lack of effectiveness.

Verrica's customers include pediatric dermatologists, dermatologists, and select pediatricians, as well as hospitals and clinics. The company has secured coverage for YCANTH (VP-102) in over 200 million lives in the United States, with assignment to both the pharmacy benefit and medical benefit.